Positive results from Factor IX-CTP comparative study in hemophilic mice

PROLOR Biotech, Inc., today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor IX (Factor IX-CTP) in Factor IX-depleted hemophilic mice.  The study was designed to measure the potential increase in clotting activity and duration of therapeutic effect of PROLOR's long-acting CTP-modified Factor IX when compared with commercially available recombinant Factor IX.  Factor IX is indicated for the treatment of acute bleeding episodes and as therapy for prevention of bleeding in hemophilia B patients.

In the study, Factor IX-CTP, when compared with commercially available Factor IX, demonstrated a significantly longer duration of clotting activity in the hemophilic mice model.  Bleeding episodes were also significantly shorter and less intense for the group treated with Factor IX-CTP.  In addition, none of the animals treated with Factor IX-CTP had any spontaneous re-bleeding events, compared with a 50% incidence of re-bleeding events for the group treated with commercial Factor IX and an 83% incidence of re-bleeding events for the untreated group.

The new study results support previous preclinical studies that demonstrated significant improvements in the half-life of Factor IX-CTP compared to commercially available Factor IX.

"We believe that this study further validates CTP as a leading platform for developing long-acting therapeutic proteins, demonstrating that the fundamental ability of CTP to extend duration of therapeutic effect while increasing biological activity is consistent across various types of proteins," noted Shai Novik, President of PROLOR.  "The utility of CTP has previously been validated for non-enzyme proteins, such as Merck's hormone therapy Elonva® and PROLOR's human growth hormone, interferon beta and erythropoietin.  With this successful Factor IX study, we have now additionally confirmed the applicability of CTP technology for the development of biobetter enzymes."

"We believe there is great need among hemophilia patients and their physicians for therapies that will provide prolonged protection from bleeding," said Dr. Abraham Havron, CEO of PROLOR.  "The encouraging efficacy seen in our preclinical hemophilia study, together with the impressive half-life extension seen in our previous studies, show that Factor IX-CTP may be able to reduce the number of injections needed by hemophilia B patients to once-weekly or less."

Dr. Havron added, "We believe that these results further confirm the clinical potential of Factor IX-CTP to become an important long-acting therapy for the treatment of acute bleeding episodes and for prevention of bleeding in hemophilia B patients.  We are moving forward with our plan to initiate our first clinical study of Factor IX-CTP in hemophilia in early 2012."

Source:

PROLOR Biotech, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Gut bacteria influence symptoms of hypopituitarism in mice